Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Rhythm · Phase 3 · Completed · Enrollment 19

NCT05194124

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Run-in Period: Setmelanotide 2 mg QDn/rn/rn/rn/r
Run-in Period: Setmelanotide 2.5 mg QDn/rn/rn/rn/r
Run-in Period: Setmelanotide 3 mg QDn/rn/rn/rn/r
DB Period: Setmelanotide 20 mg QWn/rn/rn/rn/r
DB Period: Setmelanotide 25 mg QWn/rn/rn/rn/r
DB Period: Setmelanotide 3 mg QDn/rn/rn/rn/r
DB Period: Setmelanotide 30 mg QWn/rn/rn/rn/r
OL Period: Setmelanotide 20 mg QWn/rn/rn/rn/r
OL Period: Setmelanotide 25 mg QWn/rn/rn/rn/r
OL Period: Setmelanotide 30 mg QWn/rn/rn/rn/r

Not shown

  • Run-in Period: Setmelanotide 2 mg QD: endpoint not reported
  • Run-in Period: Setmelanotide 2.5 mg QD: endpoint not reported
  • Run-in Period: Setmelanotide 3 mg QD: endpoint not reported
  • DB Period: Setmelanotide 20 mg QW: endpoint not reported
  • DB Period: Setmelanotide 25 mg QW: endpoint not reported
  • DB Period: Setmelanotide 3 mg QD: endpoint not reported
  • DB Period: Setmelanotide 30 mg QW: endpoint not reported
  • OL Period: Setmelanotide 20 mg QW: endpoint not reported
  • OL Period: Setmelanotide 25 mg QW: endpoint not reported
  • OL Period: Setmelanotide 30 mg QW: endpoint not reported